Look back at pharma news in the week to April 9, 2021

11 April 2021

By Barbara Obstoj-Cardwell. Editor

In COVID-19 related news last week, Japan’s Takeda and Australia’s CSL Ltd reported that the project they are leading, dubbed CoVig-19 Plasma Alliance, had failed to meet Phase III goals, and is therefore concluded. AstraZeneca’s COVID-19 vaccine, now called Vaxzevria, came under the spotlight last week regarding possible links to blood clots. On the regulatory front, Acadia Pharmaceuticals had a setback, as the US Food and Drug Administration issued a complete response letter (CRL) relating to its supplementary Biologics License (sBLA) for Nuplazid as a treatment for dementia-related psychosis. FibroGen revealed that some false data had been presented on its drug candidate roxadustat for the treatment of chronic kidney disease-associated anemia. Also, Provention Bio revealed problems with its regulatory filing for diabetes candidate teplizumab.

Takeda, CSL Behring fold big plasma alliance after Ph III flop

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK